Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Mohty, M."" wg kryterium: Autor

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 156
Tytuł:
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT.
Autorzy:
Nagler A; Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel. .
Labopin M; EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France.; Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France.
Blaise D; Programme de Transplantation and Therapie Cellulaire Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.
Raiola AM; Ematologia e Terapie Cellulari, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Corral LL; Hospital Clínico Servicio de Hematología, Salamanca, Spain.
Bramanti S; Transplantation Unit Department of Oncology and Haematology, Istituto Clinico Humanitas, Milan, Italy.
Sica S; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.; Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.
Kwon M; Hematology Hospital GU Gregorio Marañon, Instituto de Investigacion Sanitaria Gregorio Marañon, Medicina UCM, Madrid, Spain.
Koc Y; Bone Marrow Transplant Unit, Medicana International Hospital Istanbul, Istanbuls, Turkey.
Pavlu J; Department of Haematology, Hammersmith Hospital, Imperial College, London, UK.
Kulagin A; Raisa Gorbacheva Memorial, Research Institute for Paediatric Oncology, Hematology, and Transplantation, First State Pavlov Medical University of St. Petersburg, St. Petersburg, Russia.
Busca A; SSD Trapianto di Cellule Staminali, AOU Citta' Della Salute e della Scienza, Turin, Italy.
Rodríguez AB; Hospital U. Marqués de Valdecilla, Servicio de Hematología-Hemoterapia, Santander, Spain.
Reményi P; Dél-pesti Centrumkórház - Országos Hematológiai és Infektológiai Intézet, Department Hematology and Stem Cell Transplant, Budapest, Hungary.
Schmid C; Department of Hematology and Oncology, Augsburg University Hospital, Augsburg, Germany.
Brissot E; Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, AP-HP, Sorbonne University, and INSERM UMRs 938, Paris, France.
Sanz J; Hematology Department, Hospital Universitari Politècnic La Fe, Valencia, Spain.
Bazarbachi A; Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Giebel S; Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Ciceri F; Ospedale San Raffaele, Haematology and BMT, Milan, Italy.
Mohty M; EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France.; Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2023 May 29; Vol. 16 (1), pp. 58. Date of Electronic Publication: 2023 May 29.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/methods
Leukemia, Myeloid, Acute*/complications
Graft vs Host Disease*/etiology
Adult ; Humans ; Middle Aged ; Transplantation, Haploidentical/methods ; Cyclophosphamide/therapeutic use ; Recurrence ; Transplantation Conditioning/methods ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Autorzy:
Ye Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, China.
Labopin M; EBMT Global Committee (Shanghai and Paris Offices) and Acute Leukemia Working Party, Hospital Saint-Antoine APHP and Sorbonne University, Paris, France.
Chen J; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Gulbas Z; Anadolu Medical Center Hospital Bone Marrow Transplantation Department, Kocaeli, Turkey.
Zhang X; Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical University, Chongqing, China.
Koc Y; Medicana International Hospital Istanbul, Bone Marrow Transplant Unit, Istanbul, Turkey.
Blaise D; Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.
Ciceri F; Ospedale San Raffaele S.R.L., Haematology and BMT, Milan, Italy.
Polge E; EBMT Global Committee (Shanghai and Paris Offices) and Acute Leukemia Working Party, Hospital Saint-Antoine APHP and Sorbonne University, Paris, France.
Houhou M; EBMT Global Committee (Shanghai and Paris Offices) and Acute Leukemia Working Party, Hospital Saint-Antoine APHP and Sorbonne University, Paris, France.
Li L; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, China.
Luo Y; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, China.
Wu D; National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Huang H; Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou, China. .
Mohty M; EBMT Global Committee (Shanghai and Paris Offices) and Acute Leukemia Working Party, Hospital Saint-Antoine APHP and Sorbonne University, Paris, France. mohamad.mohty@inserm.fr.; Department of Hematology and Cell Therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France. mohamad.mohty@inserm.fr.; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, APHP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France. mohamad.mohty@inserm.fr.
Gorin NC; EBMT Global Committee (Shanghai and Paris Offices) and Acute Leukemia Working Party, Hospital Saint-Antoine APHP and Sorbonne University, Paris, France. .; Department of Hematology and Cell Therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France. .; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, APHP, 184 rue du Faubourg Saint-Antoine, 75012, Paris, France. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2023 Mar 18; Vol. 16 (1), pp. 25. Date of Electronic Publication: 2023 Mar 18.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Myeloid, Acute*
Hematopoietic Stem Cell Transplantation*/adverse effects
Graft vs Host Disease*/etiology
Precursor Cell Lymphoblastic Leukemia-Lymphoma*/therapy
Adult ; Humans ; Bone Marrow ; Acute Disease ; Recurrence ; Retrospective Studies ; Transplantation Conditioning/adverse effects
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT.
Autorzy:
Baron F; Laboratory of Hematology, GIGA-I3, University of Liege and CHU of Liège, Sart-Tilman, 4000, Liège, Belgium. .
Labopin M; EBMT Paris Study Office/CEREST-TC, Paris, France.; Department of Hematology, Saint Antoine Hospital, Paris, France.; INSERM UMR 938, Paris, France.; Sorbonne University, Paris, France.
Tischer J; Department of Internal Medicine III, LMU, University Hospital of Munich, Campus Grosshadern, Munich, Germany.
Raiola AM; IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Vydra J; Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
Blaise D; Programme de Transplantation et d'immunothérapie Cellulaire, Management Sport Cancer Lab, Institut Paoli Calmettes, Aix Marseille University, Marseille, France.
Chiusolo P; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Stölzel F; University Hospital Dresden, Medizinische Klinik und Poliklinik, TU Dresden, Dresden, Germany.; University Hospital Schleswig-Holstein, Kiel, Germany.
Fanin R; Division of Hematology, Azienda Ospedaliero Universitaria di Udine, Udine, Italy.
Chevallier P; Dept. D`Hematologie, CHU Nantes, Nantes, France.
Nagler A; Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
Ciceri F; Haematology and BMT, Ospedale San Raffaele S.R.L., Milan, Italy.
Mohty M; EBMT Paris Study Office/CEREST-TC, Paris, France.; Department of Hematology, Saint Antoine Hospital, Paris, France.; INSERM UMR 938, Paris, France.; Sorbonne University, Paris, France.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2023 Feb 13; Vol. 16 (1), pp. 10. Date of Electronic Publication: 2023 Feb 13.
Typ publikacji:
Letter; Research Support, Non-U.S. Gov't
MeSH Terms:
Graft vs Host Disease*/etiology
Graft vs Host Disease*/prevention & control
Graft vs Host Disease*/drug therapy
Leukemia, Myeloid, Acute*/drug therapy
Hematopoietic Stem Cell Transplantation*/adverse effects
Humans ; Transplantation, Haploidentical/adverse effects ; Unrelated Donors ; Cyclophosphamide/therapeutic use ; Recurrence ; Transplantation Conditioning/adverse effects ; Retrospective Studies
Raport
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT.
Autorzy:
Nagler A; Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel.
Galimard JE; EBMT Statistical Unit, Paris, France.
Labopin M; EBMT Statistical Unit, Paris, France.; Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, Paris, France.; Sorbonne University, INSERM, Saint-Antoine Research Centre, Paris, France.
Blaise D; Programme de Transplantation & Therapie Cellulaire; Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.
Arcese W; Rome Transplant Network, Università Tor Vergata, Rome, Italy.
Trisolini SM; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
Wu D; First Affiliated Hospital of Soochow University, Department of Hematology, Suzhou, China.
Pigneux A; Service d'Hématologie et Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France.
Van Gorkom G; University Hospital Maastricht, Department of Internal Medicine Hematology/Oncology, Maastricht, The Netherlands.
Rubio MT; Department of Hematology, Brabois Hospital, Centre Hospitalier Régional Universitaire (CHRU), Nancy, France.
Gedde-Dahl T; Department of Hematology, Institute of Clinical Medicine, University of Oslo and Oslo University Hospital-Rikshospitalet, Oslo, Norway.
Huynh A; Hematology Department, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.
Lanza F; Romagna Transplant Network, Ravenna, Italy.
Gorin NC; Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, Paris, France.; Sorbonne University, INSERM, Saint-Antoine Research Centre, Paris, France.
Mohty M; Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, Paris, France.; Sorbonne University, INSERM, Saint-Antoine Research Centre, Paris, France.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Jan; Vol. 12 (2), pp. 1482-1491. Date of Electronic Publication: 2022 Jul 26.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/methods
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Transplantation, Autologous ; Remission Induction ; Transplantation, Homologous ; Recurrence ; Transplantation Conditioning/methods ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease.
Autorzy:
Mohty R; Division of Hematology-Oncology and Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA.
Al Hamed R; Department of Internal Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, USA.
Bazarbachi A; Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Brissot E; Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, and INSERM, Saint-Antoine Research Centre, 75012, Paris, France.
Nagler A; Hematology and Bone Marrow Transplant Unit, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Zeidan A; Division of Hematology/Oncology, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA.
Mohty M; Department of Clinical Hematology and Cellular Therapy, Saint-Antoine Hospital, AP-HP, Sorbonne University, and INSERM, Saint-Antoine Research Centre, 75012, Paris, France. mohamad.mohty@inserm.fr.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2022 Aug 31; Vol. 15 (1), pp. 124. Date of Electronic Publication: 2022 Aug 31.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*/drug therapy
Myelodysplastic Syndromes*/drug therapy
Myelodysplastic Syndromes*/genetics
Humans ; Immunomodulating Agents ; Precision Medicine
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Measurable residual disease, FLT3-ITD mutation, and disease status have independent prognostic influence on outcome of allogeneic stem cell transplantation in NPM1-mutated acute myeloid leukemia.
Autorzy:
Al Hamed R; Department of Internal Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, New York, USA.
Labopin M; Department of Hematology, EBMT Paris Office, CEREST-TC, Saint Antoine Hospital, Paris, France.
Daguindau E; Hôpital Jean Minjoz, Service d`Hématologie, Besançon, France.
Niittyvuopio R; HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland.
Huynh A; CHU - Institut Universitaire du Cancer Toulouse, Oncopole, Toulouse, France.
Socié G; Department of Hematology - BMT, Hôpital St. Louis, Paris, France.
Srour M; CHU de Lille, Université de Lille, Lille, France.
Henri Bourhis J; Department of Hematology, Gustave Roussy Cancer Campus, BMT Service, Villejuif, France.
Kröger N; University Hospital Eppendorf, Bone Marrow Transplantation Centre, Hamburg, Germany.
Tholouli E; Clinica Haematology Department, Manchester Royal Infirmary, Manchester, UK.
Choi G; Department of Hematology, University Medical Center Groningen (UMCG), University of Groningen, Groningen, The Netherlands.
Poiré X; Department of Haematology, Cliniques Universitaires St. Luc, Brussels, Belgium.
Martin H; Goethe-Universitaet, Medizinische Klinik II, Hämatologie, Medizinische Onkologie, Frankfurt, Germany.
Rubio MT; CHRU BRABOIS, Service Hématologie, Vandoeuvre-lès-Nancy, France.
Jindra P; Department of Hematology/Oncology, Charles University Hospital, Pilsen, Czech Republic.
Blaise D; Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Marseille, France.
Beelen D; Department of Bone Marrow Transplantation, University Hospital, Essen, Germany.
Labussière-Wallet H; Centre Hospitalier Lyon Sud, Service Hématologie, Lyon, France.
Nagler A; Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Bazarbachi A; Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
Mohty M; Department of Hematology, EBMT Paris Office, CEREST-TC, Saint Antoine Hospital, Paris, France.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2022 Feb; Vol. 11 (4), pp. 1068-1080. Date of Electronic Publication: 2022 Jan 20.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/methods
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/therapy
Adult ; Humans ; Mutation ; Nucleophosmin ; Prognosis ; Recurrence ; Retrospective Studies ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience.
Autorzy:
Paviglianiti A; Sorbonne University, Service d'Hématologie Clinique et Thérapie cellulaire, Hôpital Saint-Antoine, Paris, France.; University Campus Bio-Medico, Rome, Italy.
Sestili S; Sorbonne University, Service d'Hématologie Clinique et Thérapie cellulaire, Hôpital Saint-Antoine, Paris, France.
Bianchessi A; Sorbonne University, Service d'Hématologie Clinique et Thérapie cellulaire, Hôpital Saint-Antoine, Paris, France.; Department of Molecular Medicine, University of Pavia and Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Memoli M; Sorbonne University, Service d'Hématologie Clinique et Thérapie cellulaire, Hôpital Saint-Antoine, Paris, France.; Department of Medicine and Surgery, Hematology and Hematopoietic Stem Cell Transplant Center, University of Naples Federico II, Naples, Italy.
Dulery R; Sorbonne University, Service d'Hématologie Clinique et Thérapie cellulaire, Hôpital Saint-Antoine, Paris, France.
Banet A; Sorbonne University, Service d'Hématologie Clinique et Thérapie cellulaire, Hôpital Saint-Antoine, Paris, France.
Van De Wyngaert Z; Sorbonne University, Service d'Hématologie Clinique et Thérapie cellulaire, Hôpital Saint-Antoine, Paris, France.
Belhocine R; Sorbonne University, Service d'Hématologie Clinique et Thérapie cellulaire, Hôpital Saint-Antoine, Paris, France.
Ledraa T; Sorbonne University, Service d'Hématologie Clinique et Thérapie cellulaire, Hôpital Saint-Antoine, Paris, France.
Malard F; Sorbonne University, Service d'Hématologie Clinique et Thérapie cellulaire, Hôpital Saint-Antoine, Paris, France.
Mohty M; Sorbonne University, Service d'Hématologie Clinique et Thérapie cellulaire, Hôpital Saint-Antoine, Paris, France.
Brissot E; Sorbonne University, Service d'Hématologie Clinique et Thérapie cellulaire, Hôpital Saint-Antoine, Paris, France.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2022 Feb; Vol. 63 (2), pp. 443-449. Date of Electronic Publication: 2021 Sep 29.
Typ publikacji:
Journal Article
MeSH Terms:
Graft vs Host Disease*/prevention & control
Hematopoietic Stem Cell Transplantation*/adverse effects
Cyclophosphamide/adverse effects ; Humans ; Lung ; Retrospective Studies ; Transplantation Conditioning
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Role of D(T)PACE-based regimens as treatment of multiple myeloma with extramedullary relapse or refractory disease.
Autorzy:
Huynh T; Service d'Hématologie et thérapie cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France.
Corre E; Service d'Hématologie et thérapie cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France.
Lemonnier MP; Service d'Hématologie et thérapie cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France.
Duléry R; Service d'Hématologie et thérapie cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France.
Marjanovic Z; Service d'Hématologie et thérapie cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France.
Jaff N; Service d'Hématologie et thérapie cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France.
Lapusan S; Service d'Hématologie et thérapie cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France.
Mohty M; Service d'Hématologie et thérapie cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France.; Sorbonne Université, Paris, France.; INSERM UMRs 938, Paris, France.
Garderet L; Service d'Hématologie et thérapie cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France.; Sorbonne Université, Paris, France.
Coppo P; Service d'Hématologie et thérapie cellulaire, Hôpital Saint-Antoine, AP-HP, Paris, France.; Sorbonne Université, Paris, France.; Centre de Référence des Microangiopathies Thrombotiques (CNR-MAT), AP-HP, Paris, France.; Centre de Recherche des Cordeliers, INSERM UMRS 1138, Paris, France.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2021 Sep; Vol. 62 (9), pp. 2235-2241. Date of Electronic Publication: 2021 Apr 01.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*
Multiple Myeloma*/drug therapy
Multiple Myeloma*/genetics
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Neoplasm Recurrence, Local ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT.
Autorzy:
Sanz J; Hematology Department, Hospital Universitari i Politècnic La Fe, Valencia, Spain. sanz_.; CIBERONC, Instituto Carlos III, Madrid, Spain. sanz_.
Galimard JE; EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France.
Labopin M; EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France.
Afanasyev B; RM Gorbacheva Research Institute, Pavlov University, Lva Tolstogo 6/8, 197022, Saint-Petersburg, Russian Federation.
Sergeevich MI; RM Gorbacheva Research Institute, Pavlov University, Lva Tolstogo 6/8, 197022, Saint-Petersburg, Russian Federation.
Angelucci E; Hematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Kröger N; Bone Marrow Transplantation Centre, University Hospital Eppendorf, Hamburg, Germany.
Koc Y; Medicana International, Istanbul, Turkey.
Ciceri F; Ospedale San Raffaele s.r.l., Haematology and BMT, Milan, Italy.
Diez-Martin JL; Hematology Department, Hospital GU Gregorio Marañon, Instituto de Investigación Sanitaria Gregorio Marañon, Universidad Complutense Madrid, Madrid, Spain.
Arat M; Florence Nightingale Sisli Hospital, Hematopoietic SCT Unit, Istanbul, Turkey.
Sica S; Istituto di Ematologia, Universita Cattolica S. Cuore, Rome, Italy.
Rovira M; Department of Hematology, Hospital Clinic, Institute of Hematology and Oncology, Barcelona, Spain.; August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Aljurf M; King Faisal Specialist Hospital and Research Centre Oncology (Section of Adult Haematolgy/BMT), Riyadh, Saudi Arabia.
Tischer J; Department of Internal Medicine III, Grosshadern, LMU, University Hospital of Munich, Munich, Germany.
Savani B; Vanderbilt University Medical Center, Nashville, TN, USA.
Ruggeri A; Ospedale San Raffaele s.r.l., Haematology and BMT, Milan, Italy.
Nagler A; Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.
Mohty M; Department of Hematology, and INSERM UMRs 938, Hopital Saint Antoine, Sorbonne University, Paris, France.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2021 May 28; Vol. 14 (1), pp. 84. Date of Electronic Publication: 2021 May 28.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Antineoplastic Agents, Alkylating/*therapeutic use
Cyclophosphamide/*therapeutic use
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Adult ; Aged ; Female ; Graft vs Host Disease/etiology ; Graft vs Host Disease/prevention & control ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Transplantation, Haploidentical/adverse effects ; Transplantation, Homologous/adverse effects ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia.
Autorzy:
Dholaria B; Department of Hematology-Oncology, Vanderbilt University Medical Center, 220 Pierce Ave, 777 Preston Research Building, Nashville, TN, 37232, USA. .
Labopin M; EBMT ALWP Office, Hôpital Saint-Antoine, Paris, France.
Sanz J; Hematology Department, University Hospital La Fe, Valencia, Spain.
Ruggeri A; Department of Pediatric Hematology and Oncology IRCCS, Ospedale Pediatrico Bambino Gesù, Rome, Italy.
Cornelissen J; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Labussière-Wallet H; Hôpital Lyon Sud, Hospices Civils de Lyon, Pierre Bénite, France.
Blaise D; Programme de Transplantation and Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.
Forcade E; Hôpital Haut-Leveque, CHU Bordeaux, Pessac, France.
Chevallier P; Department of D'Hematologie, CHU Nantes, Nantes, France.
Grassi A; Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
Zubarovskaya L; RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian Federation.
Kuball J; Department of Haematology, University Medical Centre, Utrecht, The Netherlands.
Ceballos P; Département d'Hématologie Clinique, CHU Lapeyronie, Montpellier, France.
Ciceri F; Ospedale San Raffaele S.R.L., Haematology and BMT, Milan, Italy.
Baron F; CHU and University of Liège, Liège, Belgium.
Savani BN; Department of Hematology-Oncology, Vanderbilt University Medical Center, 220 Pierce Ave, 777 Preston Research Building, Nashville, TN, 37232, USA.
Nagler A; Chaim Sheba Medical Center, Tel Hashomer, Israel.; ALWP Office Hôpital Saint-Antoine, Paris, France.
Mohty M; EBMT ALWP Office, Hôpital Saint-Antoine, Paris, France.; Service d'Hématologie Clinique et Thérapie Cellulaire, Hôpital Saint-Antoine, UMRs 938, AP-HP, Sorbonne University, and INSERM, Paris, France.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2021 May 03; Vol. 14 (1), pp. 76. Date of Electronic Publication: 2021 May 03.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Cord Blood Stem Cell Transplantation/*methods
Cyclophosphamide/*therapeutic use
Hematopoietic Stem Cell Transplantation/*methods
Leukemia, Myeloid, Acute/*drug therapy
Transplantation Conditioning/*methods
Adolescent ; Adult ; Aged ; Cyclophosphamide/pharmacology ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Unrelated Donors ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Autorzy:
Nagler A; Hematology Division, Chaim Sheba Medical Center, 52621, Tel Hashomer, Israel. .
Labopin M; EBMT Paris Study Office, Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France.
Houhou M; ALWP of the EBMT Paris office, Paris, France.
Aljurf M; King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
Mousavi A; Shariati Hospital, Hematology-Oncology and BMT Research, Tehran, Islamic Republic of Iran.
Hamladji RM; Service Hématologie Greffe de Moëlle, Centre Pierre Et Marie Curie, Alger, Algeria.
Al Zahrani M; King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Bondarenko S; Raisa Gorbacheva Memorial Institute of Children Oncology Hematology and Transplantation, First Pavlov State Medical University, Saint-Petersburg, Russian Federation.
Arat M; Hematopoietic Stem Cell Transplantation Unit, Sisli Florence Nightingale Hospital, Istanbul, Turkey.
Angelucci E; Hematology and Transplant Center, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Koc Y; Medicana International, Istanbul, Turkey.
Gülbas Z; Bone Marrow Transplantation Department, Anadolu Medical Center Hospital, Kocaeli, Turkey.
Sica S; Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy.; Istituto di Ematologia, Università Cattolica del Sacro Cuore, Rome, France.
Bourhis JH; Department of Hematology, Gustave Roussy Cancer Center, Villejuif, France.
Canaani J; Hematology Division, Sheba Medical Center, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Brissot E; Hematology Department, Hôpital Saint Antoine, Service d'Hématologie et Thérapie Cellulaire, Paris, France.
Giebel S; Department of Bone Marrow Transplantation and Hematology-Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland.
Mohty M; Department of Haematology, Saint Antoine Hospital, INSERM UMR 938, Sorbonne University, Paris, France.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2021 Apr 01; Vol. 14 (1), pp. 53. Date of Electronic Publication: 2021 Apr 01.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Hematopoietic Stem Cell Transplantation/*methods
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Transplantation Conditioning/*methods
Transplantation, Haploidentical/*methods
Adolescent ; Adult ; Aged ; Europe ; Hematopoietic Stem Cell Transplantation/mortality ; Humans ; Male ; Middle Aged ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Retrospective Studies ; Siblings ; Survival Analysis ; Tissue Donors ; Transplantation Conditioning/mortality ; Transplantation, Haploidentical/mortality ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed/refractory acute myelogenous leukemia - a study of the Acute Leukemia Working Party of the EBMT.
Autorzy:
Heinicke T; Department of Hematology and Oncology, Otto-von-Guericke University, Magdeburg, Germany.
Labopin M; Department of Hematology and Cell Therapy, Hopital Saint-Antoine, Paris, France.; Acute Leukemia Working Party of EBMT Office, Hopital St. Antoine, Paris, France.
Polge E; Acute Leukemia Working Party of EBMT Office, Hopital St. Antoine, Paris, France.
Stelljes M; Department of Internal Medicine A, University of Muenster, Muenster, Germany.
Ganser A; Department of Haematology, Hemostasis, Oncology, Hannover Medical School, Hannover, Germany.
Tischer J; Department of Internal Medicine III, Hematopoietic Stem Cell Transplantation, University Hospital of Munich-Campus Grosshadern, LMU, Munich, Germany.
Brecht A; DKD Helios-Klinikum, KMT-Abteilung, Wiesbaden, Germany.
Kröger N; Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany.
Beelen DW; Department of Bone Marrow Transplantation, University Hospital Essen, Essen, Germany.
Scheid C; I Department of Medicine, University of Cologne, Cologne, Germany.
Bethge W; Medizinische Klinik II, University Tübingen, Tübingen, Germany.
Dreger P; Medizinische Klinik u. Poliklinik V, University of Heidelberg, Heidelberg, Germany.
Bunjes D; Klinik fuer Innere Medzin III, University Hospital Ulm, Ulm, Germany.
Wagner E; Department of Hematology, Oncology and Pneumology, University Medical Center Mainz, Mainz, Germany.
Platzbecker U; Medical Clinic and Policlinic 1, University Hospital Leipzig, Leipzig, Germany.
Savani BN; Division of Hematology-Oncology, Vanderbilt University Medical Center, Brentwood, TN, USA.
Nagler A; Acute Leukemia Working Party of EBMT Office, Hopital St. Antoine, Paris, France.; Hematology Division and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer and Tel Aviv University, Tel HaShomer, Israel.
Mohty M; Department of Hematology and Cell Therapy, Hopital Saint-Antoine, Paris, France.; Acute Leukemia Working Party of EBMT Office, Hopital St. Antoine, Paris, France.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2021 Feb; Vol. 62 (2), pp. 399-409. Date of Electronic Publication: 2020 Oct 11.
Typ publikacji:
Journal Article
MeSH Terms:
Graft vs Host Disease*
Hematopoietic Stem Cell Transplantation*
Leukemia, Myeloid, Acute*/therapy
Aged ; Busulfan ; Humans ; Middle Aged ; Retrospective Studies ; Transplantation Conditioning
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.
Autorzy:
Memoli M; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; Department of Medicine and Surgery, Hematology and Hematopoietic Stem Cell Transplant Center, University of Naples Federico II, Naples, Italy.
Paviglianiti A; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
Malard F; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.
Battipaglia G; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.
Brissot E; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.
Médiavilla C; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.
Bianchessi A; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; Department of Molecular Medicine, University of Pavia, Pavia, Italy.
Banet A; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
Van de Wyngaert Z; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
Ledraa T; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
Belhocine R; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
Sestili S; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
Lapusan S; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
Hirsch P; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.; AP-HP, Service d'Hématologie biologique, Hôpital Saint Antoine, Paris, France.
Favale F; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.; AP-HP, Service d'Hématologie biologique, Hôpital Saint Antoine, Paris, France.
Boussaroque A; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.; AP-HP, Service d'Hématologie biologique, Hôpital Saint Antoine, Paris, France.
Bonnin A; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
Vekhoff A; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.
Legrand O; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.
Mohty M; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.
Duléry R; Department of Hematology and Cellular Therapy, Saint Antoine Hospital, AP-HP, Paris, France.; INSERM, UMRs 938, Paris, France.; Sorbonne Université, APHP, Hôpital Saint-Antoine, Paris, France.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2021 Feb; Vol. 62 (2), pp. 419-427. Date of Electronic Publication: 2020 Oct 05.
Typ publikacji:
Journal Article
MeSH Terms:
Graft vs Host Disease*/etiology
Hematopoietic Stem Cell Transplantation*/adverse effects
Primary Myelofibrosis*/diagnosis
Primary Myelofibrosis*/therapy
Adult ; Aged ; Busulfan/adverse effects ; Humans ; Middle Aged ; Thiotepa ; Transplantation Conditioning ; Vidarabine/analogs & derivatives
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors.
Autorzy:
Brissot E; Sorbonne Université, AP-HP, INSERM UMRs938, Paris, France. .; Service d'Hématologie clinique et de Thérapie cellulaire, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, 184, rue du Faubourg Saint Antoine, 75012, Paris, France. .
Labopin M; European Society for Blood and Marrow Transplantation Paris Study Office/CEREST-TC, Paris, France.
Moiseev I; R.M. Gorbacheva Memorial Institute of Oncology, Hematology and Transplantation, Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russian Federation.
Cornelissen JJ; Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Meijer E; Amsterdam University Medical Center, VU Medical Center, Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands.
Van Gorkom G; Dept. Internal Medicine, Hematology/Oncology, University Hospital Maastricht, Maastricht, The Netherlands.
Rovira M; Apheresis & Cellular Therapy Unit, Department of Hemotherapy and Hemostasis, ICMHO, Hospital Clínic, University of Barcelona, Barcelona, Spain.
Ciceri F; Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Milan, Italy.; University Vita-Salute San Raffaele, Milan, Italy.
Griskevicius L; Hematology, Oncology & Transfusion Center, Vilnius University Hospital Santaros Klinikos, Vilnius University, Vilnius, Lithuania.
Blaise D; Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.
Forcade E; CHU Bordeaux, Hospital Haut-Leveque, Pessac, France.
Mistrik M; Department of Haematology and Transfusion Medicine, University Hospital and Comenius University, Bratislava, Slovak Republic.
Mielke S; Department of Internal Medicine II, University Hospital of Würzburg, Oberdürrbacher Str. 6, D-97080, Würzburg, Germany.
Bulabois CE; Department of Hematology, CHU de Grenoble, Grenoble, France.
Niittyvuopio R; HUCH Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki, Finland.
Deconinck E; Service d'Hématologie, Hopital Jean Minjoz, Besançon, France.
Ruggeri A; Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Milan, Italy.; University Vita-Salute San Raffaele, Milan, Italy.
Sanz J; Department of Haematology, University Hospital La Fe, University of Valencia, Valencia, Spain.; Department of Haematology, Centro de Investigación Biomédica en Red de Cáncer, Instituto Carlos III, Madrid, Spain.
Spyridonidis A; Department of Internal Medicine, Bone Marrow Transplantation Unit, University Hospital of Patras, Patras, Greece.
Savani B; Long Term Transplant Clinic, Vanderbilt University Medical Center, Nashville, TN, USA.
Giebel S; Department of Bone Marrow Transplantation and Oncohematology, Maria Sklodowska-Curie Memorial Cencer Center and Institute of Oncology, Gliwice, Poland.
Nagler A; Hematology Division, BMT and Cord Blood Bank, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Mohty M; Sorbonne Université, AP-HP, INSERM UMRs938, Paris, France.; Service d'Hématologie clinique et de Thérapie cellulaire, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Antoine, 184, rue du Faubourg Saint Antoine, 75012, Paris, France.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2020 Jul 03; Vol. 13 (1), pp. 87. Date of Electronic Publication: 2020 Jul 03.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Unrelated Donors*
Antilymphocyte Serum/*therapeutic use
Cyclophosphamide/*therapeutic use
Hematopoietic Stem Cell Transplantation/*adverse effects
Immunosuppressive Agents/*therapeutic use
Leukemia, Myeloid, Acute/*therapy
Adolescent ; Adult ; Aged ; Allografts ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cause of Death ; Combined Modality Therapy ; Disease-Free Survival ; Female ; Graft Survival ; Graft vs Host Disease/drug therapy ; Graft vs Host Disease/epidemiology ; Graft vs Host Disease/prevention & control ; Histocompatibility ; Humans ; Incidence ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/drug therapy ; Male ; Middle Aged ; Propensity Score ; Recurrence ; Remission Induction ; Retrospective Studies ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Allogeneic stem cell transplantation for peripheral T cell lymphomas: a retrospective study in 285 patients from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Autorzy:
Mamez AC; Hematology Department, Hôpitaux Universitaires de Genève, 4 rue Gabrielle-Perret- Gentil, 1205, Geneva, Switzerland. .
Dupont A; APHP Department of Biostatistics and Medical Information, Hôpital Saint-Louis; ECSTRA Team, CRESS UMR 1153, INSERM, Paris Diderot University, Paris, France.
Blaise D; Institut Paoli-Calmettes, Aix Marseille Université, CNRS, INSERM, CRCM, Marseille, France.
Chevallier P; Hematology Department, CHU Hôtel-Dieu, Nantes, France.
Forcade E; Service d'Hématologie Clinique et Thérapie Cellulaire, CHU Bordeaux, Bordeaux, France.
Ceballos P; Hematology Department, Hôpital St Eloi, Montpellier, France.
Mohty M; Hematology Department, Saint Antoine Hospital, Paris, France.
Suarez F; Hematology Department, Hôpital Necker, Paris, France.
Beguin Y; Department of Medicine, Division of Hematology, University of Liège, Liège, Belgium.
Peffault De Latour R; Bone Marrow Transplant Unit, Department of Hematology, Saint-Louis Hospital, University Paris-Diderot, Paris, France.
Rubio MT; Hematology Department, CHRU Nancy, Hôpital Barbois, Vandœuvre-les, Nancy, France.
Tournilhac O; Hematology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France.
Nguyen S; Department of Hematology, Hôpital Pitié Salpêtrière, Paris, France.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2020 May 19; Vol. 13 (1), pp. 56. Date of Electronic Publication: 2020 May 19.
Typ publikacji:
Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/mortality
Hematopoietic Stem Cell Transplantation*/statistics & numerical data
Lymphoma, T-Cell, Peripheral/*therapy
Adolescent ; Adult ; Aged ; Allografts ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Combined Modality Therapy ; Graft vs Host Disease/etiology ; Graft vs Host Disease/mortality ; Graft vs Host Disease/prevention & control ; Humans ; Immunosuppressive Agents/therapeutic use ; Incidence ; Infections/mortality ; Kaplan-Meier Estimate ; Lymphoma, Large-Cell, Anaplastic/mortality ; Lymphoma, Large-Cell, Anaplastic/therapy ; Lymphoma, T-Cell, Peripheral/mortality ; Middle Aged ; Prognosis ; Progression-Free Survival ; Radiotherapy, Adjuvant ; Recurrence ; Remission Induction ; Retrospective Studies ; Salvage Therapy ; Transplantation Conditioning/methods ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT.
Autorzy:
Sanz J; Hematology Department, Hospital Universitari i Politècnic La Fe, Avinguda Fernando Abril Martorell, 106, 46026, Valencia, Spain. sanz_.; CIBERONC, Instituto Carlos III, Madrid, Spain. sanz_.
Galimard JE; EBMT Paris Office, Hospital Saint Antoine, Paris, France.
Labopin M; EBMT Paris Office, Hospital Saint Antoine, Paris, France.; Department of Hematology, Hopital Saint Antoine, Sorbonne University, Paris, France.
Afanasyev B; First State Pavlov Medical University of St. Petersburg, Raisa Gorbacheva Memorial Research Institute for Paediatric Oncology, Hematology, and Transplantation, St Petersburg, Russia.
Angelucci E; Department of Haematology, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Ciceri F; Haematology and BMT, Ospedale San Raffaele s.r.l., Milano, Italy.
Blaise D; Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.
Cornelissen JJ; Department of Hematology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Meijer E; Department of Hematology (Br 250), VU University Medical Center, Amsterdam, The Netherlands.
Diez-Martin JL; Hematology Department, Hospital GU Gregorio Marañon, Instituto de Investigación sanitaria Gregorio Marañon, Universidad Complutense Madrid, Madrid, Spain.
Koc Y; Stem Cell Transplant Unit, Medical Park Hospitals, Antalya, Turkey.
Rovira M; Dept. of Hematology, Institute of Hematology & Oncology, Hospital Clinic, Barcelona, Spain.; Institut d'Investigació Biomèdica August Pi I Sunyer (IDIBAPS), Institut Josep Carreras, University of Barcelona, Barcelona, Spain.
Castagna L; Transplantation Unit, Department of Oncology and Haematology, Istituto Clinico Humanitas, Milan, Italy.
Savani B; Vanderbilt University Medical Center, Nashville, TN, USA.
Ruggeri A; Department of Pediatric Hematology and Oncology, IRCCS Bambino Gesù Children's Hospital, Piazza S.Onofrio, 4, Rome, Italy.
Nagler A; Division of Hematology and Bone Marrow Transplantation, The Chaim Sheba Medical Center, Tel-Hashomer, Ramat-Gan, Israel.; ALWP of the EBMT office, Saint Antoine Hospital, Paris, France.
Mohty M; Department of Hematology, Hopital Saint Antoine, Sorbonne University, Paris, France.
Pokaż więcej
Corporate Authors:
Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2020 May 06; Vol. 13 (1), pp. 46. Date of Electronic Publication: 2020 May 06.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Hematopoietic Stem Cell Transplantation*/adverse effects
Cyclophosphamide/*therapeutic use
Graft vs Host Disease/*prevention & control
Immunosuppressive Agents/*therapeutic use
Leukemia, Myeloid, Acute/*therapy
Adult ; Aged ; Donor Selection ; Female ; Graft vs Host Disease/etiology ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Siblings ; Tissue Donors ; Transplantation, Haploidentical/adverse effects ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
Autorzy:
Pavlů J; Centre for Haematology, Imperial College London at Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK. .
Labopin M; Department of Haematology, EBMT Paris Study Office/CEREST-TC/Saint Antoine Hospital, Paris, France.
Niittyvuopio R; Stem Cell Transplantation Unit, HUCH Comprehensive Cancer Center, Helsinki, Finland.
Socié G; Hematology-BMT, Saint Louis Hospital, Paris, France.
Yakoub-Agha I; Service des Maladies du Sang, Hopital Claude Huriez, CHRU Lille, Lille, France.
Wu D; Department of Hematology, the First Affiliated Hospital of Soochow University, Soochow, China.
Remenyi P; Délpesti Centrumkórház-Országos Hematológiai és Infektológiai Intézet, Budapest, Hungary.
Passweg J; University Hospital Basel, Basel, Switzerland.
Beelen DW; Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany.
Aljurf M; Department of Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Kröger N; Bone Marrow Transplantation Centre, University Hospital Eppendorf, Hamburg, Germany.
Labussière-Wallet H; Service d'hématologie, Centre Hospitalier Lyon Sud, Lyon, France.
Perić Z; Zavod za hematologiju, Klinika za unutarnje bolesti, Zagreb, Croatia.
Giebel S; Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.
Nagler A; Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer and Sackler School of Medicine, Ramat Gan, Israel.
Mohty M; Department of Haematology, EBMT Paris Study Office/CEREST-TC/Saint Antoine Hospital, Paris, France.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2019 Oct 23; Vol. 12 (1), pp. 108. Date of Electronic Publication: 2019 Oct 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Myeloablative Agonists*
Neoplasm, Residual*
Hematopoietic Stem Cell Transplantation/*methods
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Adolescent ; Adult ; Aged ; Female ; Graft vs Host Disease ; Humans ; Male ; Middle Aged ; Registries ; Remission Induction ; Retrospective Studies ; Transplantation Conditioning ; Transplantation, Homologous ; Whole-Body Irradiation ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Impact of cyclosporine A concentration on acute graft-vs-host disease incidence after haploidentical hematopoietic cell transplantation.
Autorzy:
Stocker N; INSERM, Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, Paris, France.
Duléry R; Service d'Hématologie Clinique, AP-HP, Hôpital Saint-Antoine, Paris, France.
Battipaglia G; Service d'Hématologie Clinique, AP-HP, Hôpital Saint-Antoine, Paris, France.
Brissot E; INSERM, Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, Paris, France.; Service d'Hématologie Clinique, AP-HP, Hôpital Saint-Antoine, Paris, France.
Médiavilla C; INSERM, Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, Paris, France.; Service d'Hématologie Clinique, AP-HP, Hôpital Saint-Antoine, Paris, France.
Sestili S; Service d'Hématologie Clinique, AP-HP, Hôpital Saint-Antoine, Paris, France.
Paviglianiti A; Service d'Hématologie Clinique, AP-HP, Hôpital Saint-Antoine, Paris, France.
Ledraa T; INSERM, Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, Paris, France.; Service d'Hématologie Clinique, AP-HP, Hôpital Saint-Antoine, Paris, France.
Mohty R; Service d'Hématologie Clinique, AP-HP, Hôpital Saint-Antoine, Paris, France.
Bazarbachi A; Service d'Hématologie Clinique, AP-HP, Hôpital Saint-Antoine, Paris, France.
Belhocine R; Service d'Hématologie Clinique, AP-HP, Hôpital Saint-Antoine, Paris, France.
Vekhoff A; Service d'Hématologie Clinique, AP-HP, Hôpital Saint-Antoine, Paris, France.
Ruggeri A; Service d'Hématologie Clinique, AP-HP, Hôpital Saint-Antoine, Paris, France.
Mohty M; INSERM, Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, Paris, France.; Service d'Hématologie Clinique, AP-HP, Hôpital Saint-Antoine, Paris, France.
Malard F; INSERM, Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, Paris, France.; Service d'Hématologie Clinique, AP-HP, Hôpital Saint-Antoine, Paris, France.
Pokaż więcej
Źródło:
European journal of haematology [Eur J Haematol] 2019 Jul; Vol. 103 (1), pp. 10-17. Date of Electronic Publication: 2019 May 14.
Typ publikacji:
Journal Article
MeSH Terms:
Cyclosporine/*administration & dosage
Graft vs Host Disease/*etiology
Graft vs Host Disease/*prevention & control
Hematopoietic Stem Cell Transplantation/*adverse effects
Immunosuppressive Agents/*administration & dosage
Acute Disease ; Adolescent ; Adult ; Aged ; Cyclophosphamide/administration & dosage ; Cyclosporine/pharmacokinetics ; Drug Monitoring ; Female ; Graft vs Host Disease/diagnosis ; Graft vs Host Disease/epidemiology ; Hematologic Neoplasms/complications ; Hematologic Neoplasms/therapy ; Humans ; Immunosuppressive Agents/pharmacokinetics ; Incidence ; Male ; Middle Aged ; Recurrence ; Risk Factors ; Time-to-Treatment ; Transplantation Conditioning ; Transplantation, Haploidentical ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).
Autorzy:
Saraceni F; Department of Internal Medicine and Hematology, AV3, ASUR Marche, Macerata, Italy. .; Acute Leukemia Working Party - European Society for Blood and Marrow Transplantation, Paris, France. .
Labopin M; EBMT Paris study office- CEREST-TC, Paris, France, Department of Haematology, Saint Antoine Hospital, Paris, France.
Brecht A; Deutsche Klinik fuer Diagnostik, KMT Zentrum, Wiesbaden, Germany.
Kröger N; University Hospital Eppendorf, Bone Marrow Transplantation Centre, Hamburg, Germany.
Eder M; Department of Haematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany.
Tischer J; Klinikum Grosshadern Med. Klinik III, Munich, Germany.
Labussière-Wallet H; Centre Hospitalier Lyon Sud, Pavillon Marcel Bérard -Bat 1G, Service Hematologie, Lyon, France.
Einsele H; Universitaetsklinikum Wuerzburg, Med. Klinik und Poliklinik II, Wuerzburg, Germany.
Beelen D; University Hospital, Dept. of Bone Marrow Transplantation, Essen, Germany.
Bunjes D; Klinik fuer Innere Medzin III, Universitätsklinikum Ulm, Ulm, Germany.
Niederwieser D; Division of Haematology & Oncology, University Hospital Leipzig, Leipzig, Germany.
Bochtler T; University of Heidelberg, Medizinische Klinik u. Poliklinik V, Heidelberg, Germany.
Savani BN; Vanderbilt University Medical Center, Nashville, TN, USA.
Mohty M; Department of Haematology, Saint-Antoine Hospital, Paris, France.
Nagler A; EBMT Paris study office- CEREST-TC, Paris, France, Department of Haematology, Saint Antoine Hospital, Paris, France.; Department of Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2019 Apr 25; Vol. 12 (1), pp. 44. Date of Electronic Publication: 2019 Apr 25.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Busulfan/*analogs & derivatives
Busulfan/*therapeutic use
Hematopoietic Stem Cell Transplantation/*methods
Leukemia, Myeloid, Acute/*drug therapy
Thiotepa/*therapeutic use
Transplantation Conditioning/*methods
Vidarabine/*analogs & derivatives
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Busulfan/pharmacology ; Europe ; Female ; Humans ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Retrospective Studies ; Thiotepa/pharmacology ; Vidarabine/pharmacology ; Vidarabine/therapeutic use ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Ex vivo and in vivo T cell-depleted allogeneic stem cell transplantation in patients with acute myeloid leukemia in first complete remission resulted in similar overall survival: on behalf of the ALWP of the EBMT and the MSKCC.
Autorzy:
Malard F; Service d'Hématologie Clinique et Thérapie Cellulaire, AP-HP, Hôpital Saint-Antoine, Paris, F-75012, France. .; INSERM, Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, F-75012, Paris, France. .
Labopin M; Service d'Hématologie Clinique et Thérapie Cellulaire, AP-HP, Hôpital Saint-Antoine, Paris, F-75012, France.
Cho C; Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Blaise D; Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.
Papadopoulos EB; Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Passweg J; University Hospital, Hematology, Basel, Switzerland.
O'Reilly R; Bone Marrow Transplant Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Pediatrics, Weill Cornell Medical College, New York, NY, USA.
Forcade E; CHU Bordeaux, Hôpital Haut-leveque, Pessac, France.
Maloy M; Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Volin L; Stem Cell Transplantation Unit, HUCH Comprehensive Cancer Center, Helsinki, Finland.
Castro-Malaspina H; Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Hicheri Y; Département d'Hématologie Clinique, CHU Lapeyronie, Montpellier, France.
Jakubowski AA; Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Orvain C; Service des Maladies du Sang, CHRU, Angers, France.
Giralt S; Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Mohty M; Service d'Hématologie Clinique et Thérapie Cellulaire, AP-HP, Hôpital Saint-Antoine, Paris, F-75012, France.; INSERM, Centre de Recherche Saint-Antoine (CRSA), Sorbonne Université, F-75012, Paris, France.
Nagler A; EBMT Paris Study Office/CEREST-TC, Paris, France.; Hematology Division, Chaim Sheba Medical Center, Tel-Hashomer, Israel.
Perales MA; Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. .; Department of Medicine, Weill Cornell Medical College, New York, NY, USA. .; Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 298, New York, NY, 10065, USA. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2018 Oct 20; Vol. 11 (1), pp. 127. Date of Electronic Publication: 2018 Oct 20.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Hematopoietic Stem Cell Transplantation/*methods
Leukemia, Myeloid, Acute/*therapy
Transplantation Conditioning/*methods
Transplantation, Homologous/*methods
Adult ; Aged ; Female ; Humans ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Survival Analysis ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 156

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies